CAPRELSA®( vandetanib )

Drug CAPRELSA® vandetanib Caprelsa Overview This is a summary of the European public assessment report (EPAR) for Caprelsa. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Caprelsa. How is Caprelsa used? […]

INTRON A® (interferon alfa-2b)

Drug INTRON A® interferon alfa-2b intron A Overview This is a summary of the European public assessment report (EPAR) for IntronA. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for IntronA. How is Intron A […]

IMLYGIC® (talimogene laherparepvec)

Drug IMLYGIC® talimogene laherparepvec Imlygic Overview This is a summary of the European public assessment report (EPAR) for Imlygic. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Imlygic. For practical information about using […]

ZELBORAF® (vemurafenib)

Drug ZELBORAF® vemurafenib Zelboraf Overview Zelboraf is a cancer medicine used to treat adults with melanoma (a type of skin cancer) that has spread to other parts of the body or cannot be surgically removed. Zelboraf is only for patients whose melanoma tumour cells have a specific mutation (genetic change) called ‘BRAF V600’. Zelboraf contains […]

MEKINIST® (trametinib)

Drug MEKINIST® trametinib Mekinist Overview Mekinist is a cancer medicine used to treat adults whose cancer cells have a specific genetic mutation (change) in their genes called ‘BRAF V600’. It is used for the treatment of: melanoma (a skin cancer) that has spread or cannot be removed surgically. Mekinist is used on its own or […]

LEDAGA® (chlormethine)

Drug LEDAGA® chlormethine Ledaga Overview This is a summary of the European public assessment report (EPAR) for Ledaga. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Ledaga. For practical information about using Ledaga, […]

GLIVEC® (imatinib)

Drug GLIVEC® Pembrolizumab Glivec Overview This is a summary of the European public assessment report (EPAR) for Glivec. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Glivec. How is Glivec used? Glivec treatment should […]

POTELIGEO® (mogamulizumab)

Drug POTELIGEO® Mogamulizumab Poteligeo Overview Poteligeo is a cancer medicine used to treat mycosis fungoides and Sezary syndrome – two cancers of blood cells that affect mainly the skin. It is used in patients who have received previous treatment by mouth or injection. Both mycosis fungoides and Sezary syndrome belong to a group of rare […]

LIBTAYO® (cemiplimab)

Drug LIBTAYO® Cemiplimab Libtayo Overview Libtayo is a cancer medicine used on its own to treat adults with a type of skin cancer called cutaneous squamous cell carcinoma when the cancer is locally advanced (has spread nearby) or metastatic (has spread to other parts of the body). It is used in patients who cannot have […]

OPDIVO® (Nivolumab)

Drug OPDIVO® Nivolumab Opdivo Overview Opdivo is a cancer medicine used to treat the following: melanoma, a type of skin cancer. Opdivo is used on its own or with another cancer medicine, ipilimumab, to treat adults whose cancer has spread to other parts of the body or cannot be surgically removed. It is also used […]